Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2016 / Articles / Sep / The Placebo Effect
Discovery & Development Formulation Technology and Equipment Small Molecules Ingredients Facilities & Equipment Technology & Manufacturing Small Molecules

The Placebo Effect

A warning about using lyophilization placebos that are inappropriate or incongruous with your actual product.

By David Banks 09/21/2016 1 min read

Share

We have all heard about the use of placebos in clinical trials and healthcare, but a placebo can also be useful when developing or scaling up manufacturing processes, such as lyophilization. Freeze drying is primarily used as a means of preservation, yielding a stable product that has a prolonged shelf life and can cope with ambient storage conditions (eliminating the need for an expensive and onerous cold chain). In my view, placebos are a vital tool in freeze-drying research and development projects – after all, why waste valuable amounts of active pharmaceutical ingredient (API) if you don’t need to? Often, developers find themselves faced with low availability of the API or restrictions due to high toxicity.

In development projects, the role of the placebo is not to act as a decoy, as with clinical trials, but to actually replicate, as closely as possible, the physiochemical properties of the API in terms of its freezing and freeze-drying behavior. Inappropriate use of placebo formulations is not uncommon in the industry; for example, the API may simply be removed from the formulation even though it exerts an influence on its freeze-drying behavior. I’ve also seen active protein being substituted with a common sugar, even though the sugar has very different thermal characteristics! If the API is present in very low concentrations, it can sometimes be removed completely for freeze-drying studies with no ill effect. It is also possible to replace the API with a molecule that will simulate its presence in the formulation. Care must be taken, however, in choice of the simulant to ensure that it does not alter any significant behavior shown by the product. The simulant should be a match in terms of any critical frozen state or drying events inherent to the product such as collapse, glass transitions or eutectic melts.

If there is a higher quantity of API, this can make simulant selection even more difficult, as the API is more likely to exert a strong impact on the critical properties of the formulation and how it behaves during freeze drying. Here, careful consideration must be given to the selection of an appropriate placebo formulation and, indeed, whether the use of a placebo is a viable option at all. From my own experience, designing a placebo in this instance, although difficult, is not usually impossible. The trick is to create a placebo that acts as a suitable thermal simulant. For example, if the API is a protein, it may be possible to replace it with a routine protein, such as human serum albumin or bovine serum albumin, but it is essential to characterize both the placebo and the API to ensure equivalency. It is also very important to match the overall weight/volume concentration of the placebo to the API to replicate product resistance during drying; a higher concentration formulation will give a denser structure of dried solute solution as drying progresses down from the top of the sample, giving a greater resistance to vapor flow. A placebo formulation that is less concentrated may dry quicker and give misleading results. It goes without saying that it is also important to ensure that the same materials (vials, trays, and so on) and fill depth are used for the placebo as for the actual product. You may be surprised at how many developmental scientists do not consider these parameters... Placebos really are an essential part of developing and validating the freeze-drying process and we’ll no doubt be seeing more activity in terms of formulation and reformulation with placebos in the future. The big challenge, however, will be overcoming the industry’s common misconceptions. I would like to stress that simply removing the API, or substituting it with an unsuitable alternative will definitely not give you equivalent results of how the formulation will behave when using the API. And such mistakes are very expensive. It’s important to spend time ensuring that the properties of placebo you are using are equal to the API; it will ultimately streamline the performance and productivity of your development project.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

David Banks

David rejoined Biopharma in 2013 as Senior Scientist having worked as a co-ordinator in the National Health Service and gaining experience working in a variety of analytical laboratories; David was promoted to R&D and Laboratory Manager in January 2016. Previously, David worked for Biopharma for four years from 2002 to 2006, having studied for a BSc in Neuroscience at the University of Manchester. During this original period with the company, he built up significant experience in the freeze-drying industry, providing analytical research, consultancy and cycle development for customers worldwide. He has also travelled extensively providing installation and training for Biopharma’s bespoke analytical equipment. As R&D and Laboratory Manager, David oversees the smoothly running of the lab and acts as lead consultant and Project Manager on many of our larger customer projects.

More Articles by David Banks

False

Advertisement

Recommended

False

Related Content

What About the Kids?
Formulation
What About the Kids?

December 3, 2014

0 min read

Since the late 1990s, new regulations have given us the opportunity to address the needs of the most vulnerable and demanding patients – children...

Squid-Inspired Drug Delivery
Drug Delivery Dosage Forms Formulation
Squid-Inspired Drug Delivery

April 3, 2025

4 min read

Here’s how researchers took lessons from cephalopods to develop a new capsule that can deliver drugs, including insulin and siRNA, orally

Schizophrenia and the Future of Long-Acting Therapeutics
Formulation Dosage Forms Drug Delivery
Schizophrenia and the Future of Long-Acting Therapeutics

March 11, 2025

5 min read

Long-acting injectables help with adherence, but what if an unfolding pill could provide an oral option?

The Power of Industry and Academic Collaboration
Drug Discovery Formulation
The Power of Industry and Academic Collaboration

March 13, 2025

6 min read

Purdue University’s Young Institute is tackling pharma’s toughest challenges— from mRNA stability to aseptic manufacturing.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.